Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15308 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Ken Yamamoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Japan. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Immunotherapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In non‐small‐cell lung cancer, continuous immune‐checkpoint inhibitors (ICIs) beyond progression are often used in clinical practice. On the other hand, there is almost no data on whether the concept of continuous ICIs beyond progression can be adopted in small‐cell lung cancer (SCLC). We describe the effectiveness of continuous ICIs beyond progression in SCLC. Medical courses of SCLC patients treated with chemo‐immunotherapy were retrospectively reviewed at our hospital. The study included 36 patients with a median age of 73 years (range 46–83 years) who introduced chemo‐immunotherapy between September 2019 and December 2022. Atezolizumab and durvalumab in combination with platinum plus etoposide were administered in 24 and 12 patients, respectively. The overall response rate was 67% and the disease control rate was 86%. The median progression‐free survival and time to treatment failure (TTF) were 5.1 and 10.3 months, respectively. The median cycle of ICIs was 5 (range 1–42). The median overall survival was 13.6 months. ICIs were administered beyond progression in 14 (39%) patients: five were treated again with chemo‐immunotherapy and local ablative radiotherapy, four with local ablative radiotherapy and continuous ICIs, three with chemo‐immunotherapy, and two with continuous ICIs alone. TTF exceeded 12 months in 12 (86%) of the 14 cases, six of which were still on ICIs. Adverse events ≥grade 3 were observed in 21 (58%) patients. A notable TTF suggested a benefit of continuous ICIs beyond progression. The concept could be suitably adopted and provide a favorable prognosis in selected cases of SCLC that were previously regarded as an aggressive malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Japan.
ORCID-Profile: Ken Yamamoto, Taira Ninomaru
Zitieren
APA
Yamamoto, K., Ninomaru, T., Okada, H., Hirano, K., Shimada, T., & Hata, A. (2024). Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15308
Vancouver
Yamamoto K, Ninomaru T, Okada H, Hirano K, Shimada T, Hata A. Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15308
BibTeX
@article{Yamamoto2024,
author = {Yamamoto, Ken and Ninomaru, Taira and Okada, Hideaki and Hirano, Katsuya and Shimada, Temiko and Hata, Akito},
title = {Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15308}
}
EUVIMED